<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="152918">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01726790</url>
  </required_header>
  <id_info>
    <org_study_id>HE541020</org_study_id>
    <nct_id>NCT01726790</nct_id>
  </id_info>
  <brief_title>Effect of Intravitreal Bevacizumab on Corneal Endothelium</brief_title>
  <official_title>Effect of Intravitreal Bevacizumab on Corneal Endothelium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Khon Kaen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Khon Kaen University</source>
  <oversight_info>
    <authority>Thailand: Khon Kaen University Ethics Committee for Human Research</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate corneal endothelium cell change after intravitreal Bevacizumab injection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravitreal Bevacizumab has been used by retinal specialist in treatment many retinal
      diseases. Although it not approved by FDA for treatment. In many In vitro studies, its
      showed saftey in the eyes especially for corneal endothelium cells, that important cells to
      keep cornea clear. This study use Confoscan-Corneal confocal microsope to evaluate corneal
      endothelium before and after intravitreal Bevacizumab injection in routine retinal disease
      at 6 month follow up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Corneal endothelium cell change after intravitreal Bevacizumab injection</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Measure the corneal endothelium cell using Confoscan4-Corneal confocal microscope in patient in retinal vascular clinic before and after treat with intravitreal Bevacizumab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the complication after intravitreal Bevacizumab injection</measure>
    <time_frame>6 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Corneal Endothelial Cell Loss</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patient in retinalvascular clinic with diagnosis of retinal vein occlusion with macular
        edema, diabetic macular edema, wet aged related macular degeneration and submacular
        hemorrhage)treated with intravitreal Bevacizumab
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged between 20 and 80 years old

          -  can come to regular follow up at 6 month

          -  signed written consent forms

          -  not have corneal scar, or glaucoma

          -  history of treatment with laser or anti-VEGF therapy in 3 month prior to recruit

          -  high risk in cerebrovascular and cardiovascular diseases

          -  Pregnancy and breastfeeding

          -  can undergo confocal microspopy

        Exclusion Criteria:

          -  History of intraocular surgery or ocular trauma during study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kasem Yospaiboon, MD</last_name>
    <phone>66823057231</phone>
    <email>kasem_yod@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>KKU eye center, department of Ophthalmolgy, faculty of medicine, khon kaen university</name>
      <address>
        <city>Khon kaen</city>
        <zip>4002</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yosanan Yospaiboon, Professor</last_name>
      <phone>6643363010</phone>
      <email>yosanan@kku.ac.th</email>
    </contact>
    <investigator>
      <last_name>Kasem Yospaiboon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 11, 2012</lastchanged_date>
  <firstreceived_date>November 11, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Khon Kaen University</investigator_affiliation>
    <investigator_full_name>Kasem Yospaiboon</investigator_full_name>
    <investigator_title>Kasem Yospaiboon, MD</investigator_title>
  </responsible_party>
  <keyword>corneal endothelium</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Intravitreal injection</keyword>
  <keyword>Confoscan</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Corneal Endothelial Cell Loss</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
